Reported 1 day ago
Needham has reaffirmed its Buy rating on Autolus Therapeutics (NASDAQ:AUTL) with a price target of $10, following the company's impressive second-quarter results, which included $20.9 million in net product revenue from AUCATZYL, exceeding expectations. Autolus is also expanding its Activated Treatment Centers to 46, with plans to exceed 50 by year-end, as it focuses on innovative T cell therapies for cancer and autoimmune diseases.
Source: YAHOO